PCM
VNDA icon

Prelude Capital Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Prelude Capital Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-100
Closed -$2K – 2178
2019
Q1 		$2K Sell
100
-100
-50% -$2.28K ﹤0.01% 1685
2018
Q4 		$5K Buy
+200
New +$4.7K ﹤0.01% 1627
2014
Q3 		– Sell
-18,400
Closed -$298K – 2150
2014
Q2 		$298K Buy
+18,400
New +$245K 0.04% 570

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Prelude Capital Management's VNDA Position: Q1 2026 in Review

Prelude Capital Management sold out of Vanda Pharmaceuticals (VNDA) in Q1 2026, closing a stake of 15,100 shares — an estimated $133K sold.

Prelude Capital Management first reported a position in VNDA in Q4 2013 and held it in 35 quarters. The position peaked at $262K in Q2 2023. 170 funds tracked by Wall St. Rank hold VNDA as of Q1 2026.

  • Prelude Capital Management reported no remaining Vanda Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Prelude Capital Management sold 15,100 Vanda Pharmaceuticals shares in Q1 2026, an estimated $133K.
  • Prelude Capital Management first reported a position in Vanda Pharmaceuticals in Q4 2013 and held it in 35 quarters.
  • Prelude Capital Management's Vanda Pharmaceuticals position peaked at $262K in Q2 2023.
  • 170 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.